CEL-SCI (FRA:LSR) Current Accrued Expense: €0.35 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LSR CEL-SCI Corp FRA:LSR
30 GF Score
Price €1.10
! 2 Warning Signs
View Full Analysis

What is CEL-SCI Current Accrued Expense?

CEL-SCI FRA:LSR +10.00% 30 Current Accrued Expense is €0.35 Mil as of Mar. 2026. GuruFocus rates FRA:LSR with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

CEL-SCI's Current Accrued Expense for the quarter that ended in Mar. 2026 was €0.35 Mil.

CEL-SCI's quarterly Current Accrued Expense declined from Sep. 2025 (€0.61 Mil) to Dec. 2025 (€0.37 Mil) and declined from Dec. 2025 (€0.37 Mil) to Mar. 2026 (€0.35 Mil).

CEL-SCI's annual Current Accrued Expense declined from Sep. 2023 (€0.98 Mil) to Sep. 2024 (€0.51 Mil) but then increased from Sep. 2024 (€0.51 Mil) to Sep. 2025 (€0.61 Mil).

CEL-SCI Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for CEL-SCI's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CEL-SCI Current Accrued Expense Chart

CEL-SCI Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.85 0.98 0.51 0.61

CEL-SCI Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.41 0.61 0.37 0.35
FRA:LSR
30GF Score
CEL-SCI Corp FRA:LSR
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CEL-SCI Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €0.35 Mil mean?
CEL-SCI (FRA:LSR) has a Current Accrued Expense of €0.35 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on CEL-SCI and its competitors.
Is CEL-SCI's Current Accrued Expense too high?
CEL-SCI's current Current Accrued Expense is €0.35 Mil. Overall, CEL-SCI has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does CEL-SCI's Current Accrued Expense compare to HOWL and ZIVO?
CEL-SCI's Current Accrued Expense of €0.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on CEL-SCI and its competitors. CEL-SCI's current Current Accrued Expense is €0.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CEL-SCI stock overvalued right now?
CEL-SCI (FRA:LSR) has a current Current Accrued Expense of €0.35 Mil. The current Current Accrued Expense is €0.35 Mil. CEL-SCI's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For CEL-SCI (FRA:LSR), the current Current Accrued Expense is €0.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CEL-SCI Business Description

Other Exchanges CVM:USA
Address 8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
30GF Score

Get the complete analysis for FRA:LSR

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.10
Price